Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207

Gunhild Keller, Andrew V. Schally, Timo Gaiser, Attila Nagy, Benjamin Baker, Gabor Halmos, Jörg B. Engel

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

We determined by immunohistochemistry the presence of LHRH receptors in surgical specimens of human non-Hodgkin's lymphomas (NHL) and investigated the expression of LHRH receptors in two human NHL cell lines, RL and HT by RT-PCR, Western blot and radioligand binding studies. In in vivo experiments with nude mice bearing tumours of these NHL cell lines, the efficacy of cytotoxic LHRH analogue AN-207 and its cytotoxic radical AN-201 was examined. LHRH receptors were detected in 94.1% of the human NHL specimens and in both NHL cell lines. AN-207 significantly (P < 0.01) inhibited the growth of RL and HT tumours, while the non-targeted AN-201 had no effects. Blockade of the LHRH receptors with an excess of LHRH agonist Decapeptyl suppressed the antitumour effects of AN-207. Our findings indicate that LHRH receptors expressed in a high percentage of human NHL specimens can be used for effective targeted therapy with the cytotoxic LHRH analogue AN-207.

Original languageEnglish (US)
Pages (from-to)2196-2202
Number of pages7
JournalEuropean Journal of Cancer
Volume41
Issue number14
DOIs
StatePublished - Sep 1 2005
Externally publishedYes

    Fingerprint

Keywords

  • Cytotoxic LHRH analogue AN-207
  • LHRH receptor
  • Non-Hodgkin's lymphoma
  • Targeted chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this